June 2015
Volume 56, Issue 7
ARVO Annual Meeting Abstract  |   June 2015
Sorafenib in metastatic uveal melanoma : A multicentric prospective phase II study
Author Affiliations & Notes
  • Frederic Mouriaux
    Ophthalmology, CHU, Rennes, France
  • Vincent Servois
    Institut Curie, Paris, France
  • Sophie Piperno-Neumann
    Institut Curie, Paris, France
  • Thierry Lesimple
    Centre Eugène Marquis, Rennes, France
  • Antoine Thyss
    Centre Antoine Lacassagne, Nice, France
  • Thomas Jouary
    Dermatology, CHU, Bordeaux, France
  • Eve-Marie Neidhart-Berard
    Centre Antoine Berard, Lyon, France
  • Nicolas Penel
    Centre Oscar Lambret, Lille, France
  • Corinne Delcambre
    Centre François Baclesse, Caen, France
  • Françoise Joly
    Centre François Baclesse, Caen, France
  • Footnotes
    Commercial Relationships Frederic Mouriaux, None; Vincent Servois, None; Sophie Piperno-Neumann, None; Thierry Lesimple, None; Antoine Thyss, None; Thomas Jouary, None; Eve-Marie Neidhart-Berard, None; Nicolas Penel, None; Corinne Delcambre, None; Françoise Joly, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 5347. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Frederic Mouriaux, Vincent Servois, Sophie Piperno-Neumann, Thierry Lesimple, Antoine Thyss, Thomas Jouary, Eve-Marie Neidhart-Berard, Nicolas Penel, Corinne Delcambre, Françoise Joly; Sorafenib in metastatic uveal melanoma : A multicentric prospective phase II study. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5347.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: Uveal melanoma is the most common primary ocular malignancy in adults, accounting for 70 % of all eye malignancy. Despite adequate local treatment, about 30-50 % of patients develop metastasis and the survival rate is 50% after 10 years and the median survival time is 5-7 months after development of metastasis. There is no consensual and effective treatment in metastatic uveal melanoma. Preclinical data suggest that Sorafenib, a multikinase inhibitor of cell proliferation and angiogenesis may be a potential treatment of metastatic uveal melanoma. The primary objective of this study was the non-progression rate at 6 months with 800 mg/day of Sorafenib in patient with metastatic uveal melanoma.

Methods: Multicenter, non-comparative, non-randomized, phase II study was conducted. The primary objective was to determine the non-progression rate at 6 months for patients receiving Sorafenib at dose of 400 mg twice per day orally according the RECIST criteria. Quality of Life and adverse events were evaluated. Secondary efficacy endpoints included progression-free survival, overall survival, quality of life and adverse events

Results: 32 patients were enrolled in this study and 29 patients were evaluable. Non-progression at 6 months was observed in 11 patients (38%). Non-progression at 12 months was observed in 4 patients (13%). The overall survival was 10 months. Fatigue was a frequent adverse event and limited the quality of life.

Conclusions: Sorafenib at dose of 400 mg twice per day orally showed non-progression rate at 6 months in some patients with metastatic uveal melanoma


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.